| Literature DB >> 34306960 |
Sanjay Sawant1, Rajesh Patil1, Manoj Khawate2, Vishal Zambre1, Vaibhav Shilimkar3, Suresh Jagtap2.
Abstract
Covid-19 caused by novel coronavirus, 2019-nCoV or SARS-CoV-2 has become most severe pandemic of this century. No specific therapies are available to treat Covid-19 so far. Recently, main protease (Mpro), a potential drug target from SARS-CoV-2 has been successfully crystallised. The present study is aimed at assessment of bioactive antiviral phytochemicals as potential SARS-COV-2 Mpro inhibitors, using ensemble docking, molecular dynamics and MM-PBSA calculations. Ensemble docking studies were performed with Autodock vina program. The top 5 compounds having highest binding free energy were subjected to 100 ns molecular dynamics simulations with Gromacs. The resulting trajectories of converged period of MD were further exploited in MM-PBSA calculations to derive accurate estimates of binding free energies. The MD results were analysed with respect to RMSD, RMSF and hydrogen bond formation and occupancy parameters. The drugs remdesivir and nelfinavir were used as standard drugs for comparative studies. In the docking studies five phytochemicals, dalpanitin, amentoflavone, naringin, hinokiflavone, and rutin were found having lowest binding free energies (< - 10 kcal mol-1) which is lower than standard drugs. MD studies suggested that the complexes of these five phytochemicals with Mpro stabilize with well accepted RMSD. Amongst these phytochemicals, hinokiflavove, amentoflavone and naringin were found having better binding affinity with ΔGbinging than the standard drug remdesivir. Investigations and validation of these inhibitors against SARS-CoV-2 would be helpful in bring these molecules at the clinical settings. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40203-021-00107-9.Entities:
Keywords: ADME; COVID-2019; Docking; Main protease; Molecular dynamics; SARS-COV-2
Year: 2021 PMID: 34306960 PMCID: PMC8288410 DOI: 10.1007/s40203-021-00107-9
Source DB: PubMed Journal: In Silico Pharmacol ISSN: 2193-9616
Fig. 1Binding pocket of SARS-CoV-2 Mpro. A Binding pose of co-crystallized inhibitor showing different pockets, B conformations of bound co-crystallized inhibitor (red) and docked inhibitor (yellow) at the binding site of SARS-CoV-2 Mpro, C 2D interaction diagram for co-crystallized bound ligand and, D 2D interaction diagram for docked inhibitor
Fig. 2Aligned conformations of Mpro showing the binding site and orientation of side chains of few residues
Ensemble docking results for top 10 phytochemicals
| Sr. no. | Phytochemical (Pubchem CID) | The Mpro conformation number | Binding free energy (ΔG) kcal mol−1 | Interactions at the binding site | |
|---|---|---|---|---|---|
| H-bond interactions | Hydrophobic interactions | ||||
| 1 | Rutin (5280805) | Conf_7 | − 10.4 | Thr24, Ser144, Asn142 | Ser46, Cys145, Glu166, His41, Met165, Gly143 |
| 2 | Naringin (442428) | Conf_9 | − 10.3 | Thr24, Cys145, Thr26, His41 | Thr25, Leu27, Ser144, Met49, Gln189, Leu50, His164, Thr190, Met165 |
| 3 | Dalpanitin (44257304) | Conf_0 | − 10.2 | Gly143, Leu141, Ser144, His163, Glu166 | Cys145, Asn142, His172, Met165, Thr25, Met49, Leu27, His41, Gln192 |
| 4 | Amentoflavone (5281600) | Conf_6 | − 10.2 | His41, Thr190 | Cys145, Pro168, Leu27, Thr25, Thr26, Ser144, His163, Glu166, Gln189 |
| 5 | Hinokiflavone (5281627) | Conf_9 | − 10.0 | Asn119, Gly143, Asn28, Cys145 | His41, Met49, Leu27, Thr26, Thr25, Gln189, Met165, Glu166, His164 |
| 6 | Agathisflavone (5281599) | Conf_21 | − 10.0 | Thr190, Cys145, Glu166 | Met165, His41, Leu141, Thr25, Leu27, His163, Gln189, Met49, His164 |
| 7 | Azadirachtin (52813032) | Conf_20 | − 9.9 | Gln189, Gly143, Cys145, Ser144, Glu166 | Cys44, His41, Leu27, Thr26, Thr25, His163, Met165, Leu167, Met49 |
| 8 | Morelloflavone (5464454) | Conf_22 | − 9.4 | Glu166, His164, Tyr54, Arg188 | Met165, His163, Cys145, His41, Asp187, Thr190, Leu167, Pro52, Gln189 |
| 9 | Robustaflavone (5281694) | Conf_22 | − 9.2 | His163 | Met49, His41, His172, Glu168, Cys145, His164, Tyr54, Thr25, Gly143 |
| 10 | Marsdenoside (11343196) | Conf_12 | − 8.8 | Asn142, Thr24, Gly143 | His41, Pro168, Met165, Leu27, Thr26, Cys44, Ser46, Cys145, Met49 |
| 11 | Remdesivir (121304016) | Conf_12 Conf_15 | − 9.0 | Glu166, Cys145, Ser144 | His41, Cys44, Met49, Leu27, Thr25, Gln189, Thr190, His163, Asn142 |
| 12 | Nelfinavir (64143) | Conf_21 | − 8.5 | Cys145, Ser144, Gly143, His172, Phe140 | His41, Glu166, Met165, Pro168, Thr190, Tyr54, His164, His163, Leu141 |
Fig. 3Docked poses of ligands in the corresponding most favourable conformation of Mpro. A Rutin, B remdesivir, and C nelfinavir
Fig. 4Docked poses of A naringin and B dalpanitin
Fig. 5Docked poses of A amentoflavone and B hinokiflavone
Fig. 62D-interaction diagrams for docked poses of other phytochemicals
Fig. 7Root mean square deviations in Mpro backbone atoms and phytochemical’s atoms (DAL dalpanitin, HIN hinokiflavone, AME amentoflavone, RUT rutin, REM remdesivir, NAR naringin)
Average, minimum and maximum values of few MDS evaluations
| Parameter | Dalpanitin | Hinoki-flavone | Amento-flavone | Rutin | Naringin | Remdesivir |
|---|---|---|---|---|---|---|
| Average | 0.217 | 0.280 | 0.240 | 0.232 | 0.253 | 0.301 |
| Maximum | 0.342 | 0.391 | 0.368 | 0.344 | 0.409 | 0.430 |
| Minimum | 0.045 | 0.055 | 0.045 | 0.038 | 0.041 | 0.040 |
| Average | 0.164 | 0.197 | 0.109 | 0.222 | 0.144 | 0.253 |
| Maximum | 0.263 | 0.307 | 0.219 | 0.322 | 0.228 | 0.362 |
| Minimum | 0.018 | 0.022 | 0.022 | 0.041 | 0.027 | 0.090 |
| Average | 0.134 | 0.144 | 0.164 | 0.145 | 0.186 | 0.191 |
| Maximum | 0.551 | 0.587 | 0.565 | 0.339 | 0.438 | 0.537 |
| Minimum | 0.045 | 0.053 | 0.059 | 0.053 | 0.059 | 0.060 |
| Average | 2.223 | 2.206 | 2.265 | 2.228 | 2.207 | 2.300 |
| Maximum | 2.278 | 2.240 | 2.310 | 2.272 | 2.264 | 2.370 |
| Minimum | 2.179 | 2.165 | 2.217 | 2.190 | 2.152 | 2.228 |
Fig. 8Root mean square fluctuations in the side chain atoms of residues when complexed with phytochemicals. (S1’, S2, S1, S4 represents the respective pockets in Mpro)
Fig. 9Radius of gyration representing the compactness of protein structure
Fig. 10Number of hydrogen bonds formed between the molecules and the residues at the binding site of SARS-CoV-2 Mpro protein
Fig. 11Hydrogen bond occupancy percentage for the molecules. The respective atoms of each molecule involved in hydrogen bond formation are shown in the 3D structures of the molecules
Estimates of different interaction energies of MM-PBSA calculations
| Compound ID | van der Waal energy (kJ mol−1) | Electrostattic energy (kJ mol−1) | Polar solvation energy (kJ mol−1) | SASA energy (kJ mol−1) | Binding energy (kJ mol−1) |
|---|---|---|---|---|---|
| Dalpanitin | − 116.383 (12.852) | − 27.793 (20.341) | 114.910 (28.772) | − 15.018 (2.140) | − 44.284 (9.925) |
| Hinokiflavone | − 190.126 (13.180) | − 39.192 (11.177) | 169.929 (21.726) | − 21.479 (1.705) | − 80.868 (16.646) |
| Amentoflavone | − 183.032 (12.200) | − 52.456 (9.619) | 182.168 (17.116) | − 20.471 (1.210) | − 73.791 (8.534) |
| Rutin | − 197.796 (15.983) | − 66.631 (23.870) | 236.312 (21.347) | − 20.981 (1.238) | − 49.095 (14.757) |
| Naringin | − 190.726 (7.356) | − 18.878 (8.448) | 161.540 (12.986) | − 20.914 (0.861) | − 68.978 (8.328) |
| Remdesivir; | − 161.493 (17.564) | − 64.115 (6.902) | 189.853 (22.297) | − 20.018 (1.379) | − 55.772 (12.978) |
Standard deviations are given in parentheses